SCHEMBL5520923

SCHEMBL5520923

COC(=O)Cc1c(-c2ccc(S(=O)(=O)NC3CCCCC3)c(Cl)c2)[nH]c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
EGFR P00533 2/20 0.43
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CCR8 P51685 2/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
GLA P06280 1/20 0.40
BRD4 O60885 2/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
KDM4E B2RXH2 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877960 0.93 BRD4 (0.47) ALDH1A1L3MBTL1EGFRMEN1LMNA
SCHEMBL5514881 0.90 ALDH1A1 (0.46) ALDH1A1L3MBTL1MEN1LMNAKMT2A
SCHEMBL2878378 0.88 TLR8 (0.45) ALDH1A1EGFRTLR8TLR7GAA
SCHEMBL5516894 0.88 BRD4 (0.48) EGFRMEN1LMNAKMT2ATLR8
SCHEMBL27720121 0.88 ALDH1A1 (0.43) ALDH1A1L3MBTL1MEN1LMNAKMT2A
SCHEMBL5622868 0.88 BRD4 (0.52) L3MBTL1EGFRSMN1; SMN2TLR8TLR7
SCHEMBL5520104 0.85 GLA (0.53) ALDH1A1EGFRMEN1LMNAKMT2A
SCHEMBL5518928 0.85 ALDH1A1 (0.45) ALDH1A1L3MBTL1MEN1LMNAKMT2A
SCHEMBL5510592 0.84 ALDH1A1 (0.48) ALDH1A1EGFRLMNAKMT2ASMN1; SMN2
SCHEMBL5620480 0.84 BRD4 (0.46) ALDH1A1L3MBTL1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265278-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-11-15 US disclosed
EP-1844011-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS Aventis Pharmaceuticals Inc. (US) 2007-10-17 EP disclosed
WO-2006081343-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265278-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS PTGDR2, PTGDR, CYSLTR2 ALDH1A1 1779/4885L3MBTL1 3567/4885EGFR 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.